Natural Short-term Course of Recurrent Macular Edema Following Intravitreal Bevacizumab Therapy in Branch Retinal Vein Occlusion
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To evaluate the 3-month natural course of recurrent macular edema secondary to branch retinal veinocclusion (BRVO) treated with intravitreal bevacizumab. Methods: This retrospective, observational study included 36 eyes with macular edema secondary to BRVO. All patients were initially treated with intravitreal bevacizumab for macular edema. Recurrence of macular edemawas either not treated (untreated group) or treated with a single intravitreal bevacizumab injection (treatedgroup). Central foveal thickness (CFT) and best-corrected visual acuity (BCVA) were compared at the time ofrecurrence and 3 months later. Results: At the time of recurrence, the mean CFT and logarithm of the minimum angle of resolution BCVA were484.9 ± 124.1 μm and 0.58 ± 0.26 in the untreated group (n = 19) and 456.3 ± 126.8 μm and 0.51 ± 0.21 in thetreated group (n = 17), respectively. Three months later, the mean CFT and BCVA had changed to 493.7 ±123.9 μm and 0.62 ± 0.29 in the untreated group and 294.7 ± 104.4 μm and 0.40 ± 0.24 in the treated group,respectively. The differences in CFT and BCVA between the two time points were not significant in the untreatedgroup (p = 0.106 and p = 0.687, respectively), whereas statistically significant differences were noted inthe treated group (p = 0.002 and p < 0.001, respectively). Conclusions: Unlike the first episode of macular edema following BRVO, recurrent macular edema followingintravitreal bevacizumab therapy did not spontaneously resolve, suggesting the potential benefit of prompttreatment.
Abstract
Purpose: To evaluate the 3-month natural course of recurrent macular edema secondary to branch retinal veinocclusion (BRVO) treated with intravitreal bevacizumab. Methods: This retrospective, observational study included 36 eyes with macular edema secondary to BRVO. All patients were initially treated with intravitreal bevacizumab for macular edema. Recurrence of macular edemawas either not treated (untreated group) or treated with a single intravitreal bevacizumab injection (treatedgroup). Central foveal thickness (CFT) and best-corrected visual acuity (BCVA) were compared at the time ofrecurrence and 3 months later. Results: At the time of recurrence, the mean CFT and logarithm of the minimum angle of resolution BCVA were484.9 ± 124.1 μm and 0.58 ± 0.26 in the untreated group (n = 19) and 456.3 ± 126.8 μm and 0.51 ± 0.21 in thetreated group (n = 17), respectively. Three months later, the mean CFT and BCVA had changed to 493.7 ±123.9 μm and 0.62 ± 0.29 in the untreated group and 294.7 ± 104.4 μm and 0.40 ± 0.24 in the treated group,respectively. The differences in CFT and BCVA between the two time points were not significant in the untreatedgroup (p = 0.106 and p = 0.687, respectively), whereas statistically significant differences were noted inthe treated group (p = 0.002 and p < 0.001, respectively). Conclusions: Unlike the first episode of macular edema following BRVO, recurrent macular edema followingintravitreal bevacizumab therapy did not spontaneously resolve, suggesting the potential benefit of prompttreatment.
참고문헌 (27)
- Rogers SL, "Natural history of branch retinal vein occlusion: an evidence-based systematic review", Ophthalmology, 117, pp.1094~1101.e5 (2010)
- "Argon laser photocoagulation for macular edema in branch vein occlusion: the Branch Vein Occlusion Study Group", Am J Ophthalmol, 98, pp.271~282 (1984)
- Hayreh SS, "Ocular vascular occlusive disorders: natural history of visual outcome", Prog Retin Eye Res, 41, pp.1~25 (2014)
- Ramezani A, "Intravitreal triamcinolone for acute branch retinal vein occlusion: a randomized clinical trial", J Ophthalmic Vis Res, 6, pp.101~108 (2011)
- Shroff D, "Natural history of macular status in recent-onset branch retinal vein occlusion:an optical coherence tomography study", Int Ophthalmol, 28, pp.261~268 (2008)
- Moradian S, "Intravitreal bevacizumab vs. sham treatment in acute branch retinal vein occlusion with macular edema: results at 3 months (report 1)", Graefes Arch Clin Exp Ophthalmol, 249, pp.193~200 (2011)
- Kwon SI, "Comparison of natural course, intravitreal triamcinolone, and intravitreal bevacizumab for treatment of macular edema secondary to branch retinal vein occlusion", J Ocul Pharmacol Ther, 29, pp.5~9 (2013)
- Tan MH, "Randomized controlled trial of intravitreal ranibizumab versus standard grid laser for macular edema following branch retinal vein occlusion", Am J Ophthalmol, 157, pp.237~247 (2014)
- Brown DM, "Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study", Ophthalmology, 118, pp.1594~1602 (2011)
- Gunduz K, "Intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion", Eye (Lond), 22, pp.1168~1171 (2008)
- Hanada N, "Recurrence of macular edema associated with branch retinal vein occlusion after intravitreal bevacizumab", Jpn J Ophthalmol, 56, pp.165~174 (2012)
- Zhu D, "Meta-analysis of the effect of intravitreal bevacizumab in branch retinal vein occlusion", J Ocul Pharmacol Ther, 29, pp.523~529 (2013)
- 김진영, "Comparison Between Intravitreal Bevacizumab and Triamcinolone for Macular Edema Secondary to Branch Retinal Vein Occlusion", Korean Journal of Ophthalmology, 23(4), pp.259~265 (2009), 대한안과학회
- 이경민, "Comparison of Injection of Intravitreal Drugs with Standard Care in Macular Edema Secondary to Branch Retinal Vein Occlusion", Korean Journal of Ophthalmology, 28(1), pp.19~25 (2014), 대한안과학회
- Yasuda S, "Rebound of macular edema after intravitreal bevacizumab therapy in eyes with macular edema secondary to branch retinal vein occlusion", Retina, 31, pp.1075~1082 (2011)
- Matsumoto Y, "Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease", Retina, 27, pp.426~431 (2007)
- Jaissle GB, "Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion", Graefes Arch Clin Exp Ophthalmol, 249, pp.183~192 (2011)
- Yunoki T, "Treatment of macular edema due to branch retinal vein occlusion with single or multiple intravitreal injections of bevacizumab", Jpn J Ophthalmol, 56, pp.159~164 (2012)
- Yunoki T, "Effects of vitrectomy on recurrent macular edema due to branch retinal vein occlusion after intravitreal injection of bevacizumab", J Ophthalmol, 2013, pp.415974~ (2013)
- Ogino K, "Grid photocoagulation combined with intravitreal bevacizumab for recurrent macular edema associated with retinal vein occlusion", Clin Ophthalmol, 5, pp.1031~1036 (2011)
- Chen SD, "Intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion", Am J Ophthalmol, 141, pp.876~883 (2006)
- Krohne TU, "Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans", Am J Ophthalmol, 146, pp.508~512 (2008)
- Campochiaro PA, "Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion", Ophthalmology, 120, pp.795~802 (2013)
- Terui T, "Changes in areas of capillary nonperfusion after intravitreal injection of bevacizumab in eyes with branch retinal vein occlusion", Retina, 31, pp.1068~1074 (2011)
- Karagiannis DA, "Recurrence of macular edema in retinal vein occlusions after treatment with intravitreal ranibizumab (Lucentis)", Can J Ophthalmol, 46, pp.486~490 (2011)
- Noma H, "Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6", Am J Ophthalmol, 140, pp.256~261 (2005)
- Fonollosa A, "Vitreous levels of interleukine-8 and monocyte chemoattractant protein-1 in macular oedema with branch retinal vein occlusion", Eye (Lond), 24, pp.1284~1290 (2010)